SCHEMBL1407455

SCHEMBL1407455

COc1ccc(-c2c3cccc(F)c3nn2Cc2ccccc2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.45
NR1H3 Q13133 3/20 0.45
NTRK1 P04629 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
HSP90AA1 P07900 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MDM2 Q00987 1/20 0.39
GRIN1 Q05586 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407428 0.93 NR1H2 (0.47) NR1H2NR1H3ALDH1A1GAAKDM4E
SCHEMBL1407475 0.92 NR1H2 (0.46) NR1H2NR1H3ALDH1A1GAAKDM4E
SCHEMBL1407316 0.90 P2RX7 (0.40) NR1H2NR1H3L3MBTL1ALDH1A1GAA
SCHEMBL1407200 0.89 NR1H2 (0.45) NR1H2NR1H3NTRK1ALDH1A1GAA
SCHEMBL1407447 0.89 NR1H2 (0.47) NR1H2NR1H3ALDH1A1HSP90AA1KDM4E
SCHEMBL1407812 0.88 NR1H2 (0.43) NR1H2NR1H3NTRK1ATML3MBTL1
SCHEMBL1407762 0.88 NR1H2 (0.48) NR1H2NR1H3ALDH1A1GAAKDM4E
SCHEMBL1407384 0.87 KMT2A (0.48) NR1H2NR1H3L3MBTL1ALDH1A1GAA
SCHEMBL1408297 0.85 NR1H2 (0.43) NR1H2NR1H3KDM4EMEN1POLB
SCHEMBL4030775 0.84 CYP1A1 (0.39) ALDH1A1HSP90AA1KDM4EMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NTRK1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.